Advances in TNBC: New Markers for Innovative Treatments
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 December 2024 | Viewed by 5652
Special Issue Editor
Interests: castration-resistant prostate cancer (CRPC); extracellular vesicles; sex steroid hormones in cancers (breast, prostate, pancreatic and colon); triple negative breast cancer; sex steroid receptors; growth factor receptors signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and the absence of type 2 epidermal growth factor receptor (HER-2) overexpression, the classical markers used in targeted therapy. This feature makes TNBC a hard-to-treat tumor for the meager choice of effective drugs. To date, chemotherapy is the first-line treatment but, unfortunately, many TNBCs only partially respond to it.
For these reasons, TNBC represents a challenge for scientists and physicians. Many studies tried to characterize this BC subtype to find new targetable proteins to cure it and the results have certainly underlined its high heterogeneity as a principal and undisputed trait.
Many molecules, such as EGFR, PI3K, PARP, MEK, and histone deacetylase (HDAC), are mutated or hyperactivated, while others, for instance, AR and ERb, control growth and spreading, thereby all representing an attractive target to develop effective therapies in TNBC. Another weakness of TNBC is the presence of many immune cells, such as tumor-infiltrating lymphocytes, thereby immunotherapy represents another fascinating weapon to treat this incurable cancer.
This Special Issue aims to be a collection of manuscripts useful in updating knowledge on TNBC, and giving new ideas for studying, developing, and testing new drugs, effective even on more aggressive forms of this BC subtype.
I would like to invite you to contribute to this Special Issue with your research articles and reviews that include but are not limited to the following topics: molecular targets, signaling pathways, miRs, the role of epigenetics, new drugs, and targeted treatments in TNBC.
Dr. Pia Giovannelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TNBC treatment
- TNBC target
- signaling pathways in TNBC
- epigenetic modifications in TNBC
- immunotherapy
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.